We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Shire Plc ADS, Each Representing Three Ordinary Shares | NASDAQ:SHPG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 179.20 | 166.00 | 181.75 | 0 | 01:00:00 |
From May 2019 to May 2024
By Carlo Martuscelli
Shire PLC (SHP.LN) said Friday that a U.S. district court has ruled that a generic version of Adderall XR--for which a rival company had filed a new drug application--violates Shire patents, and wouldn't be allowed on the market.
The Irish-headquartered pharmaceutical company said that the Massachusetts court had ruled against competitor Abhai LLC because the proposed generic medication was in violation of a number of Shire patents. Therefore Abhai won't be allowed to bring the product to market until those patents expired.
Shire also said that the court had sanctioned Abhai for litigation misconduct, and ordered that a copy of the court's opinion be sent to the U.S. Food and Drug administration, in light of what the court said was Abhai's "pervasive corporate unwillingness to play by the rules."
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
March 23, 2018 05:50 ET (09:50 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Shire Plc ADS, Each Representing Three Ordinary Shares Chart |
1 Month Shire Plc ADS, Each Representing Three Ordinary Shares Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
